Hepatitis E virus: A potential threat for patients with liver disease and liver transplantation. Issue 2 (April 2017)

• Record Type: Journal Article
• Authors: van der Eijk, Annemiek A.; Pas, Suzan D.; de Man, Robert A.
• Is Part Of: Best practice & research. Volume 31:Issue 2(2017)
• Page Start: 143
• Page End: 150
• Publication Date: 2017-04
• Subjects: Hepatitis E virus -- Chronic infection -- Extrahepatic manifestations -- Treatment -- Ribavirin; Gastroenterology -- Periodicals; Gastrointestinal system -- Diseases -- Periodicals; Gastrointestinal Diseases; Gastroenterology; Klinische geneeskunde; Gastro-enterologie; Gastroenterology; Gastrointestinal system -- Diseases; Periodicals; 616.33005
• DOI: 10.1016/j.bpg.2017.03.006
• Languages: English
• ISSNs: 1521-6918

Abstract

Abstract: Immunocompromised patients are at risk of acquiring acute hepatitis E virus infection (HEV), leading to chronicity. Chronic HEV infection is associated with persistent viraemia, raised transaminase activity, histological features associated with chronic hepatitis and evidence of rapid development of cirrhosis. Extrahepatic manifestations have been associated with HEV. Most frequently reported are neurological disorders with predominantly involvement of the peripheral nervous system. In patients using immunosuppressive drugs antibody production is often delayed and HEV RNA detection is superior to serology to detect infection. Therapeutic options for chronic HEV includes tapering immunosuppressive and secondly ribavirin, pegylated interferon alpha (PEG-IFN). Present recommendation is to treat chronic HEV patients for 3 months, asses serum HEV RNA and stool HEV RNA and stop therapy if both are undetectable. Studies are required to determine which other antiviral agents than ribavirin and (PEG-)IFN are of clinical utility in treating HEV in the minority of patients who do not respond to ribavirin.